课题基金 / 基金详情

POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY

POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY
POLY ICLC 和 α 干扰素治疗难治性恶性肿瘤
批准号:
3853335
负责人:
J E JANIK
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

J E JANIK的其他基金

相似基金

相关文献

中文摘要
翻译
干扰素可诱导大量基因产物的合成。 这些产品起到了抗病毒和抗增殖的作用 α干扰素的作用。其中两种诱导基因产物, 2‘,5’-寡腺苷合成酶和双链抑制物(DSI) 由干扰素诱导,但需要双链RNA才能激活 他们。DSI在抑制蛋白质合成方面起主要作用 真核细胞启动因子2(eIF-2)的磷酸化 在其阿尔法亚基的丝氨酸51上。 这项研究联合使用干扰素α和Poly ICLC,a 形成双链RNA以确定最佳剂量水平 干扰素诱导DSI及Poly ICLC的最佳剂量 用于激活该激活酶。三个剂量水平的干扰素是 与Poly ICLC的四个剂量水平之一相结合。 这项研究旨在确定这种组合的毒性。 和最大耐受量。观察到剂量限制毒性。 干扰素10mU/m2+Poly ICLC 0.03 mg/m2。 毒性包括长期低血压,需要住院治疗 用于静脉输液。允许更高剂量的Poly ICLC 在不使用干扰素的情况下,以10mU/m2剂量水平给予干扰素 毒性。这些结果表明,Poly ICLC在 低剂量或高剂量的ICLC可能会降低 干扰素。
英文摘要
Interferon induces the synthesis of a large number of gene products. These products play a role in the antiviral and antiproliferative effects of alpha interferon. Two of the induced gene products, 2',5'-oligoadenylate synthetase and the double-stranded inhibitor (DSI) are induced by interferon but require double-stranded RNA to activate them. The DSI plays a major role in inhibiting protein synthesis initiation by phosphorylating the eukaryotic initiation factor 2 (eIF-2) on serine 51 of its alpha subunit. This study combined administration of interferon alpha and Poly ICLC, a form of double-stranded RNA in order to determine the optimal dose level of interferon for induction of the DSI and the optimal dose of Poly ICLC for activation of the kinase. Three dose levels of interferon were combined with one of four dose levels of Poly ICLC. This study was designed to determine the toxicity of this combination and the maximal tolerated dose. Dose limiting toxicity was observed with the combination of interferon 10 mu/m2 and Poly ICLC 0.03 mg/m2. Toxicity consisted of prolonged hypotension requiring hospitalization for intravenous fluid administration. Higher doses of Poly ICLC allowed administration of interferon at the 10 mu/m2 dose level without this toxicity. These results suggest that Poly ICLC may be more toxic at lower doses or that higher doses of ICLC may reduce the toxicity of interferon.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE II EFFICACY STUDY OF ROFERON A IN HAIRY CELL LEUKEMIA
RGM-CSF AND HIGH DOSE CARBOPLATIN THERAPY IN REFRACTORY OVARIAN CANCER
  • 批准号:
    3874539
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    J E JANIK
  • 依托单位:
PHASE IB TRIAL OF LEVAMISOLE ALONE AND IN COMBINATION WITH R-INTERFERON GAMMA
PHASE I TRIAL OF TNF AND GM-CSF
  • 批准号:
    3752523
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    J E JANIK
  • 依托单位:
海外基金